





## Indicated, Selective and Universal Depression Prevention

Olivia I. Okereke, MD, SM

Terry and Jean de Gunzburg MGH Research Scholar 2021-2026
Associate Professor of Psychiatry,
Harvard Medical School
Associate Professor in Epidemiology,
Harvard T. H. Chan School of Public Health

Disclosure: Springer Publishing, book royalties

## **NAM Prevention Framework**

Modality	Target
Indicated	Symptoms present
Selective	High-risk factors present
Universal	General population, regardless of risk status



Institute of Medicine Committee on Prevention of Mental Disorders. Reducing risks for mental disorders; 1994

## **Prevention Framework - MDD**


Modality	Target
Indicated	Presence of sub-syndromal depressive symptoms
Selective	High-risk factors: e.g., physical/functional impairment, co-morbidity, low social support, anxiety
Universal	General population, regardless of risk status

## JAMA | Original Investigation

Effect of Long-term Vitamin D<sub>3</sub> Supplementation vs Placebo on Risk of Depression or Clinically Relevant Depressive Symptoms and on Change in Mood Scores A Randomized Clinical Trial

Olivia I. Okereke, MD, SM; Charles F. Reynolds III, MD; David Mischoulon, MD, PhD; Grace Chang, MD, MPH; Chirag M. Vyas, MBBS, MPH; Nancy R. Cook, ScD; Alison Weinberg, MA; Vadim Bubes, PhD; Trisha Copeland, MS, RD; Georgina Friedenberg, MPH; I-Min Lee, MBBS, ScD; Julie E. Buring, ScD; JoAnn E. Manson, MD, DrPH

Okereke et al, Contemp Clin Trials, 2018; Okereke et al., JAMA, 2021



 Framework is guide to ongoing and future prevention (e.g., COVID era)

Can be applied as technologies evolve

 Continued innovation needed for universal prevention

Part of a larger continuum of health promotion



